Search - tctmd.com

Displaying 1 - 20 of 60

Sort: Relevancy | Date

News Daily News

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Yael L. Maxwell

December 15, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Caitlin E. Cox

October 22, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

L.A. McKeown

July 24, 2025

News Daily News

FDA Approves Triple Therapy Polypill for High Blood Pressure

Michael O'Riordan

June 10, 2025

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

L.A. McKeown

January 24, 2025

News Daily News

Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity

L.A. McKeown

December 23, 2024

News Daily News

Age Cutoffs for PFO Closure Deserve a Rethink, Researchers Urge

L.A. McKeown

October 15, 2024

News Daily News

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

Michael O'Riordan

March 20, 2024

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Caitlin E. Cox

November 07, 2023

News Features

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

L.A. McKeown

May 12, 2023

News Conference News ACC 2023

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Caitlin E. Cox

March 14, 2023

News Daily News

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Michael O'Riordan

December 30, 2022

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Daily News

FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels

Michael O'Riordan

December 22, 2021

News Daily News

FDA Approves Two Additional Indications for Rivaroxaban in Children

L.A. McKeown

December 21, 2021

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

Advertisement

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Evolocumab Gains Expanded Indication for Primary Prevention

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

FDA Approves Triple Therapy Polypill for High Blood Pressure

January 2025 Dispatch for the CV Team

Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity

Age Cutoffs for PFO Closure Deserve a Rethink, Researchers Urge

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels

FDA Approves Two Additional Indications for Rivaroxaban in Children

British Medical Groups Express Concern About Inclisiran Rollout

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content